Tag:
schizophrenia
Latest Headlines
Latest Headlines
Genes tag schizophrenia risk
An international team has tracked down a group of genes to create a profile that could predict the risk of developing schizophrenia.
Big Pharma's high-risk pursuit of CNS gold faces major market doubts
Here's an interesting number for anyone interested in the risks and rewards of drug development: Two of every three analysts and fund managers recently queried by the ISI Group say they expect that new Alzheimer's drugs in late-stage testing at Eli Lilly and Pfizer/J&J will fail.
FDA whacks Alexza Pharma with CRL for Adasuve
The FDA shot down the company's latest application because of manufacturing deficiencies related to the device used to take the inhaled antipsychotic drug, the company revealed last night.
Infant trauma, genetics combine to boost schizophrenia odds
Schizophrenia becomes increasingly likely when you combine two things: genetic risk factors plus lots of trauma, early in infancy.
Biotech startup Mnemosyne snags $5.4M A round for neuropsych R&D
A fledgling biotech in Providence, Rhode Island has put together a $5.4 million A round to fund its plans to develop new treatments for neuropsychiatric disorders. Launched nearly two years ago with
Alexza's Adasuve slapped with delayed FDA review
The FDA slammed Alexza Pharmaceuticals ( $ALXA ) with another setback this week in its drive to bring the antipsychotic drug Adasuve to market. Regulators are extending by three months their review of
Scripps discovery could lead to way to reverse schizophrenia
Existing schizophrenia treatments combat hallucinations, delusional behavior and other symptoms of the debilitating condition, with a heady number of side effects. But what if a drug could be
Alexza shares spike after antipsychotic wins weak embrace from FDA panel
Alexza Pharma ( $ALXA ) just barely managed to clear one of the big hurdles that threatened to once again block its marathon effort at winning an FDA approval of the inhaled antipsychotic treatment
Alexza Pharma shares tank on FDA's safety concerns about Adasuve
Investors appeared to get worried after FDA staffers cited worries about lung safety issues with Alexza Pharmaceuticals' ( $ALXA ) inhaled anti-agitation drug Adasuve. Shares of the developers stock
UPDATED: FDA panel recommends approving Alexza's inhaled antipsychotic in split vote
An FDA panel of experts recommended approval for Alexza Pharmaceuticals' ( $ALXA ) inhaled, fast-acting antipsychotic drug Adasuve, as long as the company limits the dose to once a day and follows
